Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900086 | 1.00 | CHEK1 (0.56) | CHEK1KCNH2 | |
| SCHEMBL29900038 | 0.92 | CHEK1 (0.68) | CHEK1KCNH2 | |
| SCHEMBL4343133 | 0.92 | CHEK1 (0.68) | CHEK1KCNH2 | |
| SCHEMBL27768326 | 0.92 | CHEK1 (0.68) | CHEK1KCNH2 | |
| SCHEMBL29900120 | 0.92 | CHEK1 (0.68) | CHEK1KCNH2 | |
| Hydrochloric Acid SCHEMBL27747351 | 0.91 | CHEK1 (0.67) | CHEK1KCNH2 | |
| SCHEMBL12922027 | 0.88 | CHEK1 (0.46) | CHEK1KCNH2 | |
| SCHEMBL8846947 | 0.86 | CHEK1 (0.56) | CHEK1KCNH2 | |
| SCHEMBL8828193 | 0.86 | CHEK1 (0.56) | CHEK1KCNH2 | |
| SCHEMBL8831254 | 0.86 | CHEK1 (0.62) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | claimed |
| CN-115038440-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115038439-A | Combination cancer therapy with CHK inhibitors | 上海华禹生物科技有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249154-B2 | Compounds and therapeutic use thereof for protein kinase inhibition | WU ZHANGGUI (US) | 2016-02-02 | — | — | US | disclosed |
| US-8962626-B2 | Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2015-02-24 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | WU ZHANGGUI (US) | 2013-06-06 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318740-B2 | Compounds for protein kinase inhibition | WU ZHANGGUI (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | WU, ZHANGGUI (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-2241569-A1 | THIENOPYRIDAZINE COMPOUNDS, THEIR PREPARATIONS, PHARMACEUTICAL COMPOSITIONS AND USES | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-10-20 | — | — | EP | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | WU ZHANGGUI | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009415-A1 | Thienopyridazine Compounds, Their Preparations, Pharmaceutical Compositions And Uses | CYP3A5, ABCC5, DPYD | CHEK1 2344/4885KCNH2 195/4885 |
| US-20090275585-A1 | Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition | CHEK2, CHEK1, PLK1 | CHEK1 2/4885KCNH2 4153/4885 |
| US-20130143887-A1 | NOVEL COMPOUNDS AND THERAPEUTIC USE THEREOF FOR PROTEIN KINASE INHIBITION | CHEK2, CHEK1, PLK1 | CHEK1 2/4885KCNH2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.